Silence Therapeutics (SLN) Net Income towards Common Stockholders (2019 - 2025)
Historic Net Income towards Common Stockholders for Silence Therapeutics (SLN) over the last 7 years, with Q3 2025 value amounting to -$21.0 million.
- Silence Therapeutics' Net Income towards Common Stockholders rose 4651.43% to -$21.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$64.5 million, marking a year-over-year increase of 2320.54%. This contributed to the annual value of -$45.3 million for FY2024, which is 1562.71% up from last year.
- As of Q3 2025, Silence Therapeutics' Net Income towards Common Stockholders stood at -$21.0 million, which was up 4651.43% from -$27.4 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Net Income towards Common Stockholders ranged from a high of $12.3 million in Q4 2024 and a low of -$39.2 million during Q3 2024
- For the 5-year period, Silence Therapeutics' Net Income towards Common Stockholders averaged around -$16.5 million, with its median value being -$16.6 million (2021).
- In the last 5 years, Silence Therapeutics' Net Income towards Common Stockholders soared by 16622.85% in 2024 and then tumbled by 56837.47% in 2025.
- Silence Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$15.1 million in 2021, then dropped by 16.64% to -$17.7 million in 2022, then decreased by 5.23% to -$18.6 million in 2023, then surged by 166.23% to $12.3 million in 2024, then tumbled by 270.36% to -$21.0 million in 2025.
- Its Net Income towards Common Stockholders was -$21.0 million in Q3 2025, compared to -$27.4 million in Q2 2025 and -$28.5 million in Q1 2025.